Apellis Pharmaceuticals, Inc. $APLS Shares Bought by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC raised its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 47.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 24,350 shares of the company’s stock after acquiring an additional 7,783 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Apellis Pharmaceuticals were worth $422,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in APLS. AQR Capital Management LLC lifted its stake in shares of Apellis Pharmaceuticals by 119.6% in the 1st quarter. AQR Capital Management LLC now owns 4,077,419 shares of the company’s stock worth $89,173,000 after acquiring an additional 2,220,977 shares during the period. Canada Pension Plan Investment Board lifted its stake in shares of Apellis Pharmaceuticals by 2,879.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 1,048,700 shares of the company’s stock worth $22,935,000 after acquiring an additional 1,013,500 shares during the period. Nuveen LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 1st quarter worth $10,765,000. Jump Financial LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 1st quarter worth $5,809,000. Finally, ING Groep NV acquired a new stake in shares of Apellis Pharmaceuticals in the 1st quarter worth $4,028,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on APLS. Wall Street Zen upgraded shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 2nd. Raymond James Financial reduced their price objective on shares of Apellis Pharmaceuticals from $52.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday, August 1st. Cantor Fitzgerald increased their target price on shares of Apellis Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Royal Bank Of Canada increased their target price on shares of Apellis Pharmaceuticals from $17.00 to $19.00 and gave the company a “sector perform” rating in a report on Friday, August 1st. Finally, Wells Fargo & Company assumed coverage on shares of Apellis Pharmaceuticals in a report on Wednesday, October 15th. They issued an “overweight” rating and a $32.00 target price for the company. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $33.47.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,000 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, October 16th. The shares were sold at an average price of $25.22, for a total transaction of $126,100.00. Following the completion of the transaction, the general counsel owned 113,730 shares in the company, valued at approximately $2,868,270.60. The trade was a 4.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director A. Sinclair Dunlop sold 31,092 shares of Apellis Pharmaceuticals stock in a transaction dated Friday, October 10th. The stock was sold at an average price of $23.72, for a total transaction of $737,502.24. Following the transaction, the director owned 3,837 shares of the company’s stock, valued at approximately $91,013.64. The trade was a 89.01% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 312,921 shares of company stock worth $8,490,866. 6.50% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Stock Performance

Shares of APLS opened at $20.73 on Friday. The company has a current ratio of 3.77, a quick ratio of 3.16 and a debt-to-equity ratio of 2.90. The stock has a market cap of $2.62 billion, a P/E ratio of -11.39 and a beta of 0.69. The company has a 50-day moving average of $25.64 and a two-hundred day moving average of $21.68. Apellis Pharmaceuticals, Inc. has a 12-month low of $16.10 and a 12-month high of $35.72.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. The company had revenue of $458.58 million during the quarter, compared to analysts’ expectations of $364.58 million. Apellis Pharmaceuticals had a negative net margin of 30.24% and a negative return on equity of 116.09%. The firm’s quarterly revenue was up 133.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.46) earnings per share. As a group, research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).